# US 2015/0150152 A1 · Chimeric Retinoid X Receptors and Their Use in a Novel Ecdysone Receptor-Based Inducible Gene Expression System

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0150152 A1
- Document ID: US20150150152A1
- Status: Published application
- Kind: A1
- Application number: 14/551,247
- Filed: 2014-11-24
- Published: 2015-05-28
- Earliest claimed: 2001-02-20
- Assignees: Intrexon Corporation
- Applicants: Intrexon Corporation
- Inventors: Marianna Zinovievna KAPITSKAYA; Subba Reddy Palli
- Web page: https://patentgrep.com/patent/US20150150152A1

## CPC

- C12N 15/635: {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline}
- C07K 14/005: from viruses
- C07K 14/39: from yeasts
- C07K 14/70567: {Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors}
- C07K 14/721: {Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor}
- C12N 15/1055: {Protein x Protein interaction, e.g. two hybrid selection}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C07K 2319/00: Fusion polypeptide
- C07K 2319/70: containing domain for protein-protein interaction
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.

## Claims

### Claim 1

A gene expression modulation system comprising:
a) a first gene expression cassette that is capable of being expressed in a host cell comprising a polynucleotide sequence that encodes a first hybrid polypeptide comprising:
i) a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated; and
ii) an ecdysone receptor ligand binding domain; and
b) a second gene expression cassette that is capable of being expressed in the host cell comprising a polynucleotide sequence that encodes a second hybrid polypeptide comprising:
i) a transactivation domain; and
ii) a chimeric retinoid X receptor ligand binding domain.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The gene expression modulation system according to claim 1, wherein the ecdysone receptor ligand binding domain of the first hybrid polypeptide is selected from the group consisting of a spruce budworm Choristoneura fumiferana ecdysone receptor ligand binding domain, a beetle Tenebrio monitor ecdysone receptor ligand binding domain, a Manduca sexta ecdysone receptor ligand binding domain, a Heliothies virescens ecdysone receptor ligand binding domain LBD, a midge Chironomus tentans ecdysone receptor ligand binding domain LBD, a silk moth Bombyx mori ecdysone receptor ligand binding domain, a fruit fly Drosophila melanogaster ecdysone receptor ligand binding domain, a mosquito Aedes aegypti ecdysone receptor ligand binding domain, a blowfly Lucilia capitata ecdysone receptor ligand binding domain, a blowfly Lucilia cuprina ecdysone receptor ligand binding domain, a Mediterranean fruit fly Ceratitis capitata ecdysone receptor ligand binding domain, a locust Locusta migratoria ecdysone receptor ligand binding domain, an aphid Myzus persicae ecdysone receptor ligand binding domain, a fiddler crab Celuca pugilator ecdysone receptor ligand binding domain, a whitefly Bamecia argentifoli ecdysone receptor ligand binding domain, a leafhopper Nephotetix cincticeps ecdysone receptor ligand binding domain, and an ixodid tick Amblyomma americanum ecdysone receptor ligand binding domain.

### Claim at position 4

4-5. (canceled)

### Claim 6 (depends on 1)

The gene expression modulation system according to claim 1, wherein the chimeric retinoid X receptor ligand binding domain of the second hybrid polypeptide comprises at least two different retinoid X receptor ligand binding domain fragments selected from the group consisting of a vertebrate species retinoid X receptor ligand binding domain fragment, an invertebrate species retinoid X receptor ligand binding domain fragment, and a non-Dipteran/non-Lepidopteran invertebrate species retinoid X receptor homolog ligand binding domain fragment.

### Claim at position 6

7-13. (canceled)

### Claim 14

A gene expression modulation system comprising:
a) a first gene expression cassette that is capable of being expressed in a host cell comprising a polynucleotide sequence that encodes a first hybrid polypeptide comprising:
i) a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated; and
ii) a chimeric retinoid X receptor ligand binding domain; and
b) a second gene expression cassette that is capable of being expressed in the host cell comprising a polynucleotide sequence that encodes a second hybrid polypeptide comprising:
i) a transactivation domain; and
ii) an ecdysone receptor ligand binding domain.

### Claim 15

(canceled)

### Claim 16 (depends on 14)

The gene expression modulation system according to claim 14, wherein the chimeric retinoid X receptor ligand binding domain of the first hybrid polypeptide comprises at least two different retinoid X receptor ligand binding domain fragments selected from the group consisting of a vertebrate species retinoid X receptor ligand binding domain fragment, an invertebrate species retinoid X receptor ligand binding domain fragment, and a non-Dipteran/non-Lepidopteran invertebrate species retinoid X receptor homolog ligand binding domain fragment.

### Claim at position 10

17-25. (canceled)

### Claim 26

A gene expression cassette comprising a polynucleotide encoding a hybrid polypeptide comprising a DNA-binding domain and a chimeric retinoid X receptor ligand binding domain.

### Claim 27 (depends on 26)

The gene expression cassette according to claim 26, wherein the chimeric retinoid X receptor ligand binding domain comprises at least two different retinoid X receptor ligand binding domain fragments selected from the group consisting of a vertebrate species retinoid X receptor ligand binding domain fragment, an invertebrate species retinoid X receptor ligand binding domain fragment, and a non-Dipteran/non-Lepidopteran invertebrate species retinoid X receptor homolog ligand binding domain fragment.

### Claim at position 13

28-31. (canceled)

### Claim 32

A gene expression cassette comprising a polynucleotide encoding a hybrid polypeptide comprising a transactivation domain and a chimeric retinoid X receptor ligand binding domain.

### Claim at position 15

33-35. (canceled)

### Claim 36

An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide encoding a truncated chimeric retinoid X receptor ligand binding domain comprising a truncation mutation, wherein the truncation mutation reduces ligand binding activity of the truncated chimeric retinoid X receptor ligand binding domain;
(b) a polynucleotide encoding a truncated chimeric retinoid X receptor binding domain comprising a truncation mutation, wherein the truncation mutation reduces steroid binding activity of the truncated chimeric retinoid X receptor ligand binding domain;
(c) a polynucleotide encoding a truncated chimeric retinoid X receptor ligand binding domain comprising a truncation mutation, wherein the truncation mutation reduces non-steroid binding activity of the truncated chimeric retinoid X receptor ligand binding domain;
(d) a polynucleotide encoding a truncated chimeric retinoid X receptor ligand binding domain comprising a truncation mutation, wherein the truncation mutation enhances ligand binding activity of the truncated chimeric retinoid X receptor ligand binding domain;
(e) a polynucleotide encoding a truncated chimeric retinoid X receptor ligand binding domain comprising a truncation mutation, wherein the truncation mutation enhances steroid binding activity of the truncated chimeric retinoid X receptor ligand binding domain;
(f) a poly nucleotide encoding a truncated chimeric retinoid X receptor ligand binding domain comprising a truncation mutation, wherein the truncation mutation enhances non-steroid binding activity of the truncated chimeric retinoid X receptor ligand binding domain;
(g) a polynucleotide encoding a truncated chimeric retinoid X receptor ligand and binding domain comprising a truncation mutation, wherein the truncation mutation increases ligand sensitivity of the truncated chimeric retinoid X receptor ligand binding domain; and
(h) a polynucleotide encoding a truncated chimeric retinoid X receptor ligand binding domain comprising a truncation mutation, wherein the truncation mutation increases ligand sensitivity of a heterodimer, wherein the heterodimer comprises the truncated chimeric retinoid X receptor ligand binding domain and a dimerization partner.

### Claim at position 17

37-44. (canceled)

### Claim 45

An isolated polynucleotide encoding a chimeric retinoid X receptor ligand binding domain, wherein the polynucleotide comprises a nucleic acid sequence selected from the group consisting of
a) nucleotides 1-348 of SEQ ID NO: 13 and nucleotides 268-630 of SEQ ID NO: 21,
b) nucleotides 1-408 of SEQ ID NO: 13 and nucleotides 337-630 of SEQ ID NO: 21,
c) nucleotides 1-465 of SEQ ID NO: 13 and nucleotides 403-630 of SEQ ID NO: 21,
d) nucleotides 1-555 of SEQ ID NO: 13 and nucleotides 490-630 of SEQ ID NO: 21,
e) nucleotides 1-624 of SEQ ID NO: 13 and nucleotides 547-630 of SEQ ID NO: 21,
f) nucleotides 1-645 of SEQ ID NO: 13 and nucleotides 601-630 of SEQ ID NO: 21, and
g) nucleotides 1-717 of SEQ ID NO: 13 and nucleotides 613-630 of SEQ ID NO: 21.

### Claim 46

(canceled)

### Claim 47

An isolated chimeric retinoid X receptor polypeptide comprising an amino acid sequence selected from the group consisting of
a) amino acids 1-116 of SEQ ID NO: 19 and amino acids 90-210 of SEQ ID NO: 27,
b) amino acids 1-136 of SEQ ID NO: 19 and amino acids 113-210 of SEQ ID NO: 27,
c) amino acids 1-155 of SEQ ID NO: 19 and amino acids 135-210 of SEQ ID NO: 27,
d) amino acids 1-185 of SEQ ID NO: 19 and amino acids 164-210 of SEQ ID NO: 27,
e) amino acids 1-208 of SEQ ID NO: 19 and amino acids 183-210 of SEQ ID NO: 27,
f) amino acids 1-215 of SEQ ID NO: 19 and amino acids 201-210 of SEQ ID NO: 27, and
g) amino acids 1-239 of SEQ ID NO: 19 and amino acids 205-210 of SEQ ID NO: 27.

### Claim 48 (depends on 1)

A method of modulating the expression of a gene in a host cell comprising the gene to be modulated comprising the steps of:
a) introducing into the host cell the gene expression modulation system according to claim 1; and
b) introducing into the host cell a ligand;
wherein the gene to be modulated is a component of a gene expression cassette comprising:
i) a response element recognized by the DNA binding domain from the first hybrid polypeptide binds;
ii) a promoter that is activated by the transactivation domain of the second hybrid polypeptide; and
iii) a gene whose expression is to be modulated;
whereby upon introduction of the ligand into the host cell, expression of the gene of b)iii) is modulated.

### Claim 49 (depends on 48)

The method according to claim 48, wherein the ligand is a compound of the formula:
wherein:
E is a (C4-C6)alkyl containing a tertiary carbon or a cyano(C3-C5)alkyl containing a tertiary carbon;
R1 is H, Me, Et, i-Pr, F, formyl, CF3, CHF2, CHCl2, CH2F, CH2Cl, CH2OH, CH2OMe, CH2CN, CN, C≡CH, 1-propynyl, 2-propynyl, vinyl, OH, OMe, OEt, cyclopropyl, CF2CF3, CH═CHCN, allyl, azido, SCN, or SCHF2;
R2 is H, Me, Et, n-Pr, i-Pr, formyl, CF3, CHF2, CHCl2, CH2F, CH2Cl, CH2OH, CH2OMe, CH2N, CN, C≡CH, 1-propynyl, 2-propynyl, vinyl, Ac, F, Cl, OH, OMe, OEt, O-n-Pr, OAc, NMe2, NEt2, SMe, SEt, SOCF3, OCF2CF2H, COEt, cyclopropyl, CF2CF3, CH═CHCN, allyl, azido, OCF3, OCHF2, O-i-Pr, SCN, SCHF2, SOMe, NH—CN, or joined with R3 and the phenyl carbons to which R2 and R3 are attached to form an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to a phenyl carbon, or a dihydropyryl ring with the oxygen adjacent to a phenyl carbon;
R3 is H, Et, or joined with R2 and the phenyl carbons to which R2 and R3 are attached to form an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to a phenyl carbon, or a dihydropyryl ring with the oxygen adjacent to a phenyl carbon;
R4, R5, and R6 are independently H, Me, Et, F, Cl, Br, formyl, CF3CHF2, CHCl2, CH2F, CH2Cl, CH2OH, CN, C≡CH, 1-propynyl, 2-propynyl, vinyl, OMe, OEt, SMe, or SEt.

### Claim 50

(canceled)

### Claim 51 (depends on 14)

A method of modulating the expression of a gene in a host cell comprising the gene to be modulated comprising the steps of:
a) introducing into the host cell the gene expression modulation system of claim 14; and
b) introducing into the host cell a ligand;
wherein the gene to be modulated is a component of a gene expression cassette comprising:
i) a response element recognized by the DNA binding domain from the first hybrid polypeptide;
ii) a promoter that is activated by the transactivation domain of the second hybrid polypeptide; and
iii) a gene whose expression is to be modulated;
whereby upon introduction of the ligand into the host cell, expression of the gene of b)iii) is modulated.

### Claim 52 (depends on 51)

The method according to claim 51, wherein the ligand is a compound of the formula:
wherein:
E is a (C4-C6)alkyl containing a tertiary carbon or a cyano(C3-C5)alkyl containing a tertiary carbon;
R1 is H, Me, Et, i-Pr, F, formyl, CF3, CHF2, CHCl2, CH2F, CH2Cl, CH2OH, CH2OMe, CH2CN, CN, C≡CH, 1-propynyl, 2-propynyl, vinyl, OH, OMe, OEt, cyclopropyl, CF2CF3, CH═CHCN, allyl, azido, SCN, or SCHF2;
R2 is H, Me, Et, n-Pr, i-Pr, formyl, CF3, CHF2, CHCl2, CH2F, CH2Cl, CH2OH, CH2OMe, CH2N, CN, C≡CH, 1-propynyl, 2-propynyl, vinyl, Ac, F, Cl, OH, OMe, OEt, O-n-Pr, OAc, NMe2, NEt2, SMe, SEt, SOCF3, OCF2CF2H, COEt, cyclopropyl, CF2CF3, CH═CHCN, allyl, azido, OCF3, OCHF2, O-i-Pr, SCN, SCHF2, SOMe, NH—CN, or joined with R3 and the phenyl carbons to which R2 and R3 are attached to form an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to a phenyl carbon, or a dihydropyryl ring with the oxygen adjacent to a phenyl carbon;
R3 is H, Et, or joined with R2 and the phenyl carbons to which R2 and R3 are attached to form an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to a phenyl carbon, or a dihydropyryl ring with the oxygen adjacent to a phenyl carbon;
R4, R5, and R6 are independently H, Me, Et, F, Cl, Br, formyl, CF3CHF2, CHCl2, CH2F, CH2Cl, CH2OH, CN, C≡CH, 1-propynyl, 2-propynyl, vinyl, OMe, OEt, SMe, or Set.

### Claim 53

(canceled)

### Claim 54 (depends on 1)

An isolated host cell comprising the gene expression modulation system according to claim 1.

### Claim at position 28

55-56. (canceled)

### Claim 57 (depends on 14)

An isolated host cell comprising the gene expression modulation system according to claim 14.

### Claim at position 30

58-59. (canceled)

### Claim 60 (depends on 54)

A non-human organism comprising the host cell of claim 54.

### Claim at position 32

61-62. (canceled)

### Claim 63 (depends on 57)

A non human organism comprising the host cell of claim 57.

### Claim at position 34

64-65. (canceled)

### Claim 66 (depends on 60)

The non-human organism of claim 60, wherein said non-human organism is a non-transgenic organism.

### Claim 67 (depends on 63)

The non-human organism of claim 63, wherein said non-human organism is a non-transgenic organism.
